Arena Scores Hefty Obesity Drug Deal With Eisai Ahead Of PDUFA Date
This article was originally published in PharmAsia News
Executive Summary
Arena Pharmaceuticals has won an early race against Vivus and Orexigen Therapeutics in finding a commercialization partner for its obesity drug candidate lorcaserin. The three companies are vying to bring the first new obesity drug to the market in over a decade, with U.S. FDA action dates for the three candidates scheduled between October and January